Tag: human acellular vessel
Humacyte submits Biologics License Application to US FDA seeking approval of...
Humacyte today announced that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of the...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in...
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
Humacyte announces positive top line results from Phase 2/3 trial of...
Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair.
A...
Clinical performance of Human Acellular Vessel amid war in Ukraine presented...
Clinical outcomes of Humacyte's investigational Human Acellular Vessel (HAV) were presented at the recent Military Health System Research Symposium (14–17 August, Kissimmee, USA), following...
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...
Humacyte today announced completion of enrolment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...
Human-tissue engineered blood vessels remain durable at six years in PAD...
Mid-term results from a phase II study of surgical bypass using the Human Acellular Vessel (HAV; Humacyte) demonstrated an overall secondary patency rate at...
Ukrainian surgeons present clinical update on Human Acellular Vessel in vascular...
Humacyte recently announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma. The update was...
Humacyte commences US phase II arterial bypass clinical trial
Humacyte has announced the initiation of a US phase II arterial bypass clinical trial of Humacyl, an investigational human acellular vessel, to test its safety...
